On Oct 16, major Wall Street analysts update their ratings for $Walgreens Boots Alliance (WBA.US)$, with price targets ranging from $7 to $16.
Morgan Stanley analyst Erin Wright maintains with a sell rating, and maintains the target price at $7.
J.P. Morgan analyst Lisa Gill maintains with a buy rating.
BofA Securities analyst Allen Lutz maintains with a sell rating, and maintains the target price at $7.5.
Barclays analyst Stephanie Davis maintains with a sell rating, and adjusts the target price from $7 to $8.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and maintains the target price at $16.
Furthermore, according to the comprehensive report, the opinions of $Walgreens Boots Alliance (WBA.US)$'s main analysts recently are as follows:
The company's Q4 report provided guidance for fiscal 2025 and data points that were more reassuring than anticipated, helping to alleviate near-term liquidity worries. Despite these positive aspects, there are still ongoing structural concerns regarding the U.S. retail pharmacy sector.
The analyst noted that Walgreens Boots Alliance has unveiled its anticipated FY25 guidance, offering a practical forecast for the company despite numerous variables. While the firm does not favor witnessing a year-over-year halving of the business's core AOI, the provided guidance aligns with expectations, accommodating a logical perspective on reimbursement, headwinds, and growth. The emphasis now shifts to implementation, with store closures and enhancements in working capital expected to draw investor scrutiny until a steady pattern for these transformations is established.
Here are the latest investment ratings and price targets for $Walgreens Boots Alliance (WBA.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月16日，多家華爾街大行更新了$沃爾格林-聯合博姿 (WBA.US)$的評級，目標價介於7美元至16美元。
摩根士丹利分析師Erin Wright維持賣出評級，維持目標價7美元。
摩根大通分析師Lisa Gill維持買入評級。
美銀證券分析師Allen Lutz維持賣出評級，維持目標價7.5美元。
巴克萊銀行分析師Stephanie Davis維持賣出評級，並將目標價從7美元上調至8美元。
TD Cowen分析師Charles Rhyee維持買入評級，維持目標價16美元。
此外，綜合報道，$沃爾格林-聯合博姿 (WBA.US)$近期主要分析師觀點如下：
該公司的Q4報告爲2025財年提供了指導，並提供了比預期更令人放心的數據點，有助於緩解近期的流動性擔憂。儘管存在這些積極因素，但美國零售藥店板塊仍然存在持續的結構性問題。
分析師指出，沃爾格林-聯合博姿發佈了其備受期待的FY25指引，爲公司提供了實用的預測，儘管存在許多變量。儘管公司不希望看到主要aoi的同比減半，但所提供的指引符合預期，爲對賠償、逆風和增長的合理觀點提供了支持。現在重點轉向實施，預計到該變革的穩定模式確立之前，關閉店鋪和增強營運資本將受到投資者的審查。
以下爲今日7位分析師對$沃爾格林-聯合博姿 (WBA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
